- Home
- BEAT vs IHTA Comparison
BEAT vs IHTA Comparison
Compare BEAT & IHTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAT
- IHTA
- Stock Information
- Founded
- BEAT 2015
- IHTA 2017
- Country
- BEAT United States
- IHTA United States
- Employees
- BEAT N/A
- IHTA N/A
- Industry
- BEAT Retail: Computer Software & Peripheral Equipment
- IHTA Finance/Investors Services
- Sector
- BEAT Technology
- IHTA Finance
- Exchange
- BEAT Nasdaq
- IHTA Nasdaq
- Market Cap
- BEAT 59.8M
- IHTA 65.8M
- IPO Year
- BEAT 2021
- IHTA N/A
- Fundamental
- Price
- BEAT $2.22
- IHTA $7.59
- Analyst Decision
- BEAT Buy
- IHTA
- Analyst Count
- BEAT 1
- IHTA 0
- Target Price
- BEAT $8.00
- IHTA N/A
- AVG Volume (30 Days)
- BEAT 78.6K
- IHTA 24.8K
- Earning Date
- BEAT 11-12-2024
- IHTA 01-01-0001
- Dividend Yield
- BEAT N/A
- IHTA 5.29%
- EPS Growth
- BEAT N/A
- IHTA N/A
- EPS
- BEAT N/A
- IHTA N/A
- Revenue
- BEAT N/A
- IHTA N/A
- Revenue This Year
- BEAT N/A
- IHTA N/A
- Revenue Next Year
- BEAT N/A
- IHTA N/A
- P/E Ratio
- BEAT N/A
- IHTA N/A
- Revenue Growth
- BEAT N/A
- IHTA N/A
- 52 Week Low
- BEAT $1.06
- IHTA $6.47
- 52 Week High
- BEAT $3.39
- IHTA $7.69
- Technical
- Relative Strength Index (RSI)
- BEAT 49.47
- IHTA 55.81
- Support Level
- BEAT $2.06
- IHTA $7.54
- Resistance Level
- BEAT $2.30
- IHTA $7.61
- Average True Range (ATR)
- BEAT 0.13
- IHTA 0.06
- MACD
- BEAT 0.01
- IHTA -0.00
- Stochastic Oscillator
- BEAT 47.76
- IHTA 78.57
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.
About IHTA Invesco High Income 2024 Target Term Fund of Beneficial Interest No par value per share
Invesco High Income 2024 Target Term is a non-diversified, closed-end management investment company. The investment objectives of the company are to provide a high level of current income and to return it to common shareholders. The company invests in securities collateralized by loans secured by real properties and other real estate related Debt securities.